1. Home
  2. LFMD vs CTNM Comparison

LFMD vs CTNM Comparison

Compare LFMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

HOLD

Current Price

$3.50

Market Cap

330.5M

Sector

Health Care

ML Signal

HOLD

Logo Contineum Therapeutics Inc. Class A Common Stock

CTNM

Contineum Therapeutics Inc. Class A Common Stock

HOLD

Current Price

$11.04

Market Cap

328.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFMD
CTNM
Founded
1994
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.5M
328.1M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
LFMD
CTNM
Price
$3.50
$11.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$10.22
$20.00
AVG Volume (30 Days)
1.7M
169.9K
Earning Date
11-17-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$250,091,814.00
N/A
Revenue This Year
$13.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
28.78
N/A
52 Week Low
$3.43
$3.35
52 Week High
$15.84
$15.25

Technical Indicators

Market Signals
Indicator
LFMD
CTNM
Relative Strength Index (RSI) 24.69 49.67
Support Level $3.43 $10.42
Resistance Level $3.84 $11.43
Average True Range (ATR) 0.28 0.80
MACD 0.01 -0.02
Stochastic Oscillator 5.18 28.10

Price Performance

Historical Comparison
LFMD
CTNM

About LFMD LifeMD Inc.

LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: